Introduction {#Sec1}
============

Liver metastases in patients with breast cancer (BCLM) have historically been associated with the worst prognosis compared to other metastatic sites such as the lungs, bone, or brain, with 5-year survival rates of only 4--12% (median survival 4--21 months) \[[@CR1]--[@CR3]\]. Breast cancer in general is a major problem of public health for women worldwide with an estimated 1.7 million women diagnosed with breast cancer in 2012 \[[@CR4]\]. A significant proportion of these patients (around 30%) will eventually develop metastatic disease (stage IV). Although systemic treatment for metastatic breast cancer has significantly improved in recent years, dissemination is still associated with poor survival.

Within current guidelines, patients with stage IV breast cancer are only eligible for palliative systemic treatment. The U.S. National Cancer Institute, among other influential organizations, does not mention liver resection as an option for metastatic breast cancer to the liver.

Considering the poor results achieved by current guidelines, the concept of oligimetastatic resection and the existence of unreachable tumor cells deep within tumors (by systemic agents) has become the driving force behind the advocates for resection of limited metastatic disease, especially if they are reactive to systemic treatment \[[@CR5]--[@CR7]\]. Patients with colorectal liver metastases, for example who undergo curative liver resection have seen remarkable results of 5-year survival rates between 30 and 40% and even 50% in selected cases with low surgical mortality or morbidity, something unthinkable for breast cancer liver metastases \[[@CR8]\]. So far, only few small retrospective series have been reported regarding the resection of BCLM and there have been no randomized control trials \[[@CR9]--[@CR25]\].

At our institution, our highly selected patients with BCLM have routinely undergone surgical resection since 1985 with previously reported promising results \[[@CR9]\]. In general, patients with limited disease experienced more favorable outcome after surgery compared to patients with more extensive tumor involvement. The real potential of prolonged survival or even "cure" in selected patients after hepatic resection is, however, still questioned and liver resection is still not offered as part of advanced breast cancer treatment strategy.

The purpose of this study was to analyze possible indications for and against liver resection in women with BCLM. Furthermore, to study the possibility of exceptional long-term survival, we focused on patients who underwent liver surgery combined with systemic treatment and survived less than 5 year and more than 5 years after liver metastases diagnosis (note: not time of liver resection) with survival beyond 5 years a rarity with current palliative guidelines. In addition, predictive factors and the possibility of "cure" were analyzed.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

All consecutive patients with BCLM, who underwent a partial hepatectomy at our center between January 1985 and December 2012, were selected. Patients were selected from our prospectively maintained institutional database, and each medical record was reviewed to update clinical and pathological data. Additional immunohistochemistry analysis was conducted in those patients with missing information and available tumor tissue. To compare with historical published studies, that reported on patients who were not operated, the starting point was defined as the moment of diagnosis of liver metastases. Patients who survived \< 5 years were compared to those who survived \> 5 years after first diagnosis of liver metastases.

Preoperative workup {#Sec4}
-------------------

To be considered for hepatic resection, all patients were required to have received stage-appropriate therapy for their primary tumor. Selection criteria for liver resection were previously presented \[[@CR9]\]. In summary, liver resection was proposed to all patients with metastases confined to the liver (or associated to very limited and stable extrahepatic disease), provided that the tumor was controlled by systemic treatment and could be completely resected with a functional remnant liver of at least 30% of the total liver volume. Preoperatively, each patient underwent abdominal ultrasonography and abdominal and thoracic computed tomography (CT), as well as a bone radionuclide scan, to determine the extent of intra- and extrahepatic disease. In the more recent patients, MRI and FDG-PET were more routinely performed to better assess the extent of intra- and extrahepatic tumor spread.

Patients with single and easily resectable liver metastases underwent early surgery without chemotherapy in case of a prolonged disease-free interval (more than 6 months). Patients with large or multiple metastases and a short disease-free interval received preoperative chemotherapy for 2--3 months. Preoperative chemotherapy was furthermore routinely indicated for patients with concomitant extrahepatic disease. The aim of preoperative chemotherapy was to limit tumor spread, to reduce tumor volume, and to exclude patients with rapidly progressive metastatic disease in whom liver resection was unlikely to provide any survival benefit. Chemotherapy consisted of a combination of the classical cytostatic drugs (such as anthracyclines, pyrimidine analogs and taxanes), hormonal therapy (aromatase inhibitors and anti-estrogen agents) or targeted therapy (monoclonal antibodies) to achieve maximum response.

The decision for hepatectomy was taken in a multidisciplinary meeting including surgeons, medical oncologists and radiologists, when the overall surgical strategy could achieve complete tumor resection and the disease was controlled by chemotherapy.

Hepatic resection {#Sec5}
-----------------

During surgery, abdominal exploration and liver ultrasonography were used to confirm tumor resectability and to evaluate the presence of extrahepatic disease. Parenchymal dissection was done using the ultrasonic dissector (Cavitron Ultrasonic Aspirator, Valleylab, Boulder, CO, USA) and a fenestrated bipolar forceps. The extent of hepatic resection was classified as minor (\< 3 hepatic segments) or major (≥ 3 hepatic segments) according to Couinaud's classification \[[@CR26]\]. Clamping of the hepatic pedicle was used if needed to control intraoperative blood loss. Tumor-free resection margins were the objective in all cases and when needed radiofrequency ablation or cryoablation was performed in combination with liver resection to achieve potentially curative surgery. Suspicious lymph nodes on the hepatic pedicle (regional) were resected for pathological review when detected, as were lymph nodes of the celiac trunk or the superior mesenteric artery (distant). However, limited extrahepatic disease was not a contraindication for hepatic resection.

Postoperative outcome and follow-up {#Sec6}
-----------------------------------

Postoperative mortality was defined as death within the first 60 days following surgery. Postoperative morbidity was defined as any postoperative adverse event, which occurred during the same period. Postoperative complications were divided into hepatic complications, which occurred within the field of liver resection (e.g., biliary fistula), and general complications, which occurred distant from the hepatic resection field (e.g., pneumonia).

All patients were regularly followed at our outpatient clinic, starting 1 month after surgery, then every 4 months for the first 2 years and every 6 months after 2 years. Follow-up consisted of a history, physical examination and radiological imaging. Abdominal ultrasound and abdominal and thoracic CT imaging were alternately performed.

Statistical analysis {#Sec7}
--------------------

Median follow-up time for the whole population was well beyond 5 years (108 months). As 5-year survival could be considered as a valuable turning point for the evaluation of outcome, the whole series was divided into two groups; patients who survived \< 5 years versus patients who survived ≥ 5 years after first diagnosis of liver metastases. Categorical variables were compared between groups by the Chi square (*χ*^2^) test and continuous variables were compared using the independent-sample *t* test. Overall survival probabilities were estimated using the Kaplan--Meier method and were compared using the log-rank test. Univariate analysis was performed to determine factors related to a survival of patients who survived beyond 5 years by using the log-rank test. To identify independent predictors of long-term survival, all factors with an univariate significance of *P* \< 0.10 were entered into a Cox proportional hazard model. To correct for missing values, multiple imputations were performed twenty times and pooled. Regressions are presented as original and imputed. All statistical analyses were performed with SPSS version 21.0 (SPSS Inc., Chicago, IL, USA), and statistical significance was determined at *P* ≤ 0.05.

Cure model {#Sec8}
----------

When a patient's observed hazard rate returns to that of the general population, that patient may be considered cured of the disease, because the risk of death is just as likely as for any member of the general population. \[[@CR27]\] The estimation of expected survival and of expected hazard of the general population was derived from population-based survival tables obtained from the French National institute of Statistics and Economics, matched by age \[[@CR28]\]. Survival time in our study group was defined as the period between hepatic resection (intervention to achieve cure) and date of death or last follow-up. The potential of cure was calculated using STATA software (StataCorp. 2011, College Station, TX: StataCorp LP) as described in several published works \[[@CR27], [@CR29]--[@CR31]\].

Results {#Sec9}
=======

Study population {#Sec10}
----------------

Between January 1985 and December 2012, 139 consecutive female patients underwent 162 hepatectomies for BCLM at our institution. Of these 139 patients, 120 (86%) underwent a single hepatectomy and 19 (14%) underwent a second hepatectomy. In 4 (3%) patients, a third hepatectomy was needed.

In total, 43 (31%) patients lived ≥ 5 years after first diagnosis of liver metastases. These 43 patients were compared to 96 (69%) patients who survived \< 5 years after liver metastases diagnosis regardless of the number of hepatectomies.

Long-term overall and disease-free survival {#Sec11}
-------------------------------------------

Median follow-up time was 108 months for the whole series. The 7- and 10-year overall survival in the ≥ 5 years group was 76% and 36%, respectively. Seven of the 43 patients (16%) are alive more than 10 years since liver metastases diagnosis (5% of the total population) with a longest survival of almost 15 years (175 months) (Figure [1](#Fig1){ref-type="fig"}) . Of the 43 patients who survived ≥ 5 years, 22 (51%) had no hepatic recurrence at last follow-up. Of the 96 patients that survived \< 5 years, 58 patients (60%) had no hepatic recurrence at last follow-up.Fig. 1Survival estimates

Median disease-free survival for the whole series was 33 months. Median disease-free survival was 25 and 43 months in the \< 5 and ≥ 5 years groups, respectively (Supplemental Table 1).

Patient and tumor characteristics comparison {#Sec12}
--------------------------------------------

Patient and tumor characteristics of both groups are summarized in Table [1](#Tab1){ref-type="table"}. Patients who survived ≥ 5 years had a shorter time interval between primary tumor and liver metastases diagnosis (43 ± 29 months vs. 50 ± 47 months, *P* = 0.026). The proportion of patients with concomitant extrahepatic disease at first hepatectomy was higher in patients who survived \< 5 years (34% vs. 19%, *P* = 0.071).Table 1Patient and tumor characteristics comparison *n* = 139\< 5-years group%≥ 5-years group%*p*Primary breast tumor^§^ Adenocarcinoma  Ductal518626930.490  Lobular81427 Differentiation  Well35130.503  Moderate34612273  Poor1934723 Surgical removal  Breast conserving424525600.140  Mastectomy51551740 Receptor status  ER positive   No9203140.737   Yes36801986  PR positive   No15357351.000   Yes28651365  Her2/Neu positive   No24699600.746   Yes1131640  ER/PR negative   No368418900.706   Yes716210 Systemic treatment  Neoadjuvant chemo   No939741950.645   Yes3325  Adjuvant chemo   No394119440.713   Yes57592456  Post op hormonal therapy   No666926610.341   Yes30311739 Post op radiotherapy  No323313300.845  Yes64673070Breast cancer liver metastases Sync  Synchronous774100.738  Metachronous87933890 Mean interval months between primary and BCLM ± SD50 ± 47 months43 ± 29 months0.026\* Mean number of BCLM ± SD2 ± 22 ± 20.803 Mean maximum tumor size ± SD, mm33 ± 1737 ± 200.312 Distribution  Bilateral293217440.232  Unilateral62682256 Concomitant extra-hepatic disease  No636635810.071  Yes3334819 Preoperative chemotherapy  No303111260.551  Yes66693274Hepatectomy Mean age at hepatectomy ± SD53 ± 11 years48 ± 10 years0.208 Timing of hepatectomy  Year \< 2000363817400.852  Year \> 200060622660 Extent of resection  Limited resection (\< 3 segments)384019440.710  Major resection (≥ 3 segments)58602456 Type of resection  Anatomical323317400.657  Wedge35371330  Anatomical+wedge29301330Histopathology Mean number of resected metastases ± SD3 ± 22 ± 20.023\* Solitary tumor  No576319460.090  Yes34372254 Mean maximum size ± SD, mm (M)30 ± 2626 ± 160.374 Resection margin  R0525825660.435  R+38421334 Hormonal receptor status  ER−40467210.021  ER+48542679  PR−576524730.516  PR+3135927  Her2/neu−607023721.000  Her2/neu+2630928 Triple negative (ER, PR, HER2/NEU)  No667528850.329  Yes2225515 Lymphatic embolus  No283521660.003\*  Yes53651134 Vascular embolus  No333724630.011\*  Yes56631437 Regional lymph node invasion  Negative for tumor cells9414570.667 Positive for tumor cells1359343 Distant lymph node invasion  Negative for tumor cells127511001.000  Positive for tumor cells42500Post hepatectomy Postoperative chemotherapy  No35379210.078  Yes61643479 Hormonal therapy after resection  No636611260.000\*  Yes33343274 Monoclonal therapy after resection  No727525580.071  Yes24251842 Recurrence  No586015350.006\*  Yes38402865 Repeat hepatectomy  No959925580.000\*  Yes111842^§^Referring center for hepatectomy, primary usually is treated in a different hospital, \**p*-value \< 0.05

The mean number of tumors resected in the ≥ 5 years group was 2 compared to 3 in \< 5 years group (*P* = 0.023). More patients in the ≥ 5 years group had a solitary liver metastasis compared to the \< 5 years group (54% vs. 37%, *P* = 0.090). Estrogen receptor positive tumors were more prevalent in the ≥ 5 years group (79% vs. 54%, *P* = 0.021). The proportion of patients with microscopic lymphatic and vascular invasion was higher in patients who survived \< 5 years (lymphatic; 65% vs. 34%, *P* = 0.003, vascular; 63% vs. 37%, *P* = 0.011). Patients who lived ≥ 5 years more frequently received hormonal therapy after hepatic resection (74% vs. 34%, *P* \< 0.000).

After hepatic resection, the proportion of hepatic recurrences was higher in the ≥ 5 years group (65% vs. 40% (*P* = *0.006*). Repeat hepatectomy was performed in 1 of the patients who survived \< 5 years and in 18 patients who survived ≥ 5 years (1% vs. 42%, *P* \< 0.000).

### Short-term outcome {#Sec13}

There were more general complications in the \< 5 years group than in the ≥ 5 years group (25% vs. 10%, *P* = 0.061). The mean hospital stay was similar in both groups; 11 vs. 10 days (*P* = 0.420). The 60-day mortality was 2% after hepatic resection for the whole series (Table [2](#Tab2){ref-type="table"}).Table 2Comorbidity\< 5-year group%≥ 5-year group%*p*Morbidity^a^ No636628720.684 Yes32341128General complications No717535900.062 Yes2425410Hepatic complications No838732820.425 Yes1213718  Biliary leakage217457  Biliary leakage+infected collection18114  Biliary leakage+noninfected collection1800  Hemorrhage00114  Infected collection43300  Noninfected collection325114Mean hospital stay, days ± SD (M)11 + 710 + 40.420*n* = 139^a^General and/or hepatic complication

Predictive factors of long-term survival {#Sec14}
----------------------------------------

At univariate analysis, factors significantly related to better survival in those patient who lived longer than 5 years were: time interval between primary tumor and hepatic metastases equal or more than 18 months, resected metastasis size smaller than 35 mm, absence of microscopic vascular invasion or combination of vascular and lymphatic invasion, absence of chemotherapy after hepatic resection (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate analysis of overall survival in patients that survived 5 years or longer after hepatectomy since date of diagnosis*n*%7 years (%)10 years (%)Median (Mo)Log rank*P* ^d^*P* ^e^Hazard ratio(95% CI)Liver metastases Time of appearance  Synchronous4900--0.462  Metachronous38887437-- Interval primary tumor and metastasis  \< 18 months61400820.010.035NS  ≥ 18 months35818140111 Tumor number  Solitaire204781521420.157  \> 123537221110 Maximal tumor size  \< 30 mm1433930940.680  ≥ 30 mm23537650111 Distribution  Unilateral225184521340.187  Bilateral17406112107 Segments involved  1184279471020.999  \> 120477936110 Chemo tx pre hepatectomy^a^  No11268048940.430  Yes32747530110 Hormone tx pre hepatectomy^b^  No368471321020.108  Yes71610050107 Targeted tx pre hepatectomy^c^  No368476361100.985  Yes71675086 Extra hepatic metastases  No358177371100.644  Yes819732991 Sites of Extrahepatic disease  Brain12  Bone25  Lung49  Lymph Node12First hepatectomy Age (E3)  \< 50 years.266077291020.613  ≥ 50 years17407544111 Hepatic resection (E3)  Minor (\< 3)174081371110.978  Major (≥ 3)26607233120 Type of resection (E3)  Anatomical194488621340.287  Both24566623107  Not Anatomical Tumor number (E3)174074411100.900  Solitaire1330694691  \> 1133010021111 Maximal tumor size (E3)  \< 35 mm266074191020.033NSNS  ≥ 35 mm12289269142 Resection margin (E3)  R0255882411110.209  R11330691991  R200------ Hormone receptor status (E3)  ER−7168686(124)0.713  ER+26608330110 No tumor cells49670(98)  PR−245676331070.543  PR+92110037112 No tumor cells49670(98)  HER2−235376371020.465  HER2+92110042111  No tumor cells49670(98) Double neg (ER−, PR−) (E3)  No819100231100.877  Yes25587739107  No tumor cells49670(98) Triple neg (ER−, PR−, HER2−) (E3)  No286584341100.874  Yes512800(81)  No tumor cells49670(98) Vascular invasion (E3)  No245692471110.06NSNS  Yes1433641391 Lymphatic Invasion (E3)  No214995501110.149  Yes11268015102 Vascular and/or lymphatic Invasion (E3)  No194495541340.078NS0.0233.4851.18410.250  Yes1944702091 Lymph Node Invasion (E3)  No497550870.222  Yes370079 Chemo tx post hepatectomy^a^ (E3−\>)  No92188731420.077NSNS  Yes34797322107 Hormone tx post hepatectomy^b^ (E3−\>)  No112689641420.0880.0070.0234.1971.21714.471  Yes32747224107 Targeted tx post hepatectomy^c^ (E3−\>)  No255883461110.209  Yes1842640110 Radiofrequency ablation, cryo ablation or arterial embolization (E3)  No388879411100.159  Yes51240082Post hepatectomy course Chemo tx peri hepatectomy^a^ (E2− \> E3−\>)  No0010050940.802  Yes40937434110 Hormone tx peri hepatectomy^b^ (E2− \> E3− \>)  No92188631420.137  Yes34797325107 Targeted tx peri hepatectomy^c^ (E2− \> E3−\>)  No235387481110.110  Yes2047590110 Hepatic Recurrence (E2.2)  No15358653(116)0.216  Yes28657129102 Interval first hepatectomy to recurence (E3− \> E2.2)  \< 12 months6146040860.670  ≥ 12 months12287326110 Tumor number  Solitair102377431110.481  \> 117407121102 Repeat hepatectomy  No1023640870.650  Yes18427447112*n* = 43*E1* primary tumor, *E2* diagnosis hepatic metastases, *E3* hepatectomy, *E4* extra hepatic metastases, *E2.2* hepatic recurrence^a^Antracyclines, pyrimidine, taxanes, platinum, vinca; single or in combinations^b^Aromatase inhibitor and anti-estrogen^c^Monoclonal antibodies, () = estimated mean+ = in ER+ or PR+ patients^d^Multivariate^e^multivariate with 20 × imputation of missing values, *tx* therapy, *NS* not significant *p* \> 0.05

Multivariate analysis identified two factors associated with long-term survival in patients who lived ≥ 5 years. Patients with microscopic vascular and/or lymphatic invasion had a three and half fold chances of dying compared to patients with no vascular or lymphatic invasion (7-year survival 70% vs. 95%, respectively, HR 3.485, range 1.184-10.250, *P* = 0.023). Patients who received hormonal therapy after hepatic resection had a four fold chance of dying compared to those that did not receive hormonal therapy (7-year survival 72% vs. 89%, respectively, HR 4.197, range 1.217--14.471, *P* = 0.023).

Probability of cure {#Sec15}
-------------------

In the entire study population, the probability of being cured of BCLM by hepatic resection combined with systemic treatment was 14% (95% CI 1.4--26.7%) (Fig. [2](#Fig2){ref-type="fig"}a). The excess of hazard after surgery started from a 2% increased risk of death early after surgical resection with respect to the general population (Fig. [2](#Fig2){ref-type="fig"}b). In the first two postoperative years, the excess hazard increased to approximately 25.8% in the entire group and was up to 32.9% in non-cured patients. After a parallel trajectory of risk of death up to 8.3 years, the entire group demonstrated a progressive reduction in the hazard while the hazard for non-cured patients progressively increased after the 4th year after surgery. The excess of hazard in the entire group decreased towards the general population hazard at 13.6 years after hepatic resection, indicating that after this time point, a patient still alive could be considered cured with 99% certainty.Fig. 2Cure model results. **a** Relative survival of the entire group of patients and the uncured patients. **b** Excess hazard rate of the entire study group and the uncured patients

Discussion {#Sec16}
==========

Long-term survival of BCLM is almost never achieved when liver metastases remain unresected \[[@CR32]--[@CR37]\]. Following hepatectomy, the 3- and 5-year survival rates were 58 and 47%, respectively, for the whole series. Of the 43 patients who survived beyond 5 years, 76% survived 7 years and even 35% survived 10 years after the time of first diagnosis. These results support the indication of hepatic resection for BCLM in selected patients and suggest that some of these patients can even be cured. This strategy also relates with current developments in local treatment of oligometastasis in other cancers such as colorectal carcinomas as part of a more individual tailored approach. The value of liver resection in these patients is also reflected in the fact that even though a portion of patients developed hepatic recurrences, long-term survival can still be achieved when repeat hepatectomy is performed.

Although systemic treatment of breast cancer patients has developed in the past decades, survival of patients with BCLM is still poor with 5-year survival rates of only 4--12% when applying current guidelines. Resection of BCLM remains controversial and is not generally accepted. Few articles have been published describing the possible benefit of surgery in mostly small study populations varying from 2 to 115 patients with a 5-year survival rate ranging from 27 to 50%.

Our series, representing a small proportion of the total number of patients with stage IV breast cancer, is without a doubt a selected group of patients. However, these results have never been expected before, based on the historical reported survival of breast cancer patients with hepatic metastases. This series is the only series to date focusing on the possibility of real long-term survival of BCLM after hepatic resection in an experienced hepatobiliary center. Two different approaches were implemented to highlight key factor that might help selecting patients with better chances of survival and a statistical cure model was constructed that compares the hazard rate of the general population to that of this series over time.

Predictive factors of ≥ 5 year survival were: interval more than 18 months between primary breast tumor and diagnosis of hepatic metastases, size of resected metastases \< 35 mm, absence of microscopic vascular and lymphatic invasion, absence of hormonal therapy after resection and repeat hepatectomy in case of tumor recurrence.

Time interval and tumor size are well-documented predictors for overall survival and are related to tumor biology. In several publications, a time interval of 1--2 years after removal of the primary tumor was reported as a significant factor of survival \[[@CR38]\].

Sadot et al. compared 69 operated patients to 98 systemically treated in a single center looking at historically selected patients for treatment groups \[[@CR39]\]. Even though they concluded that hepatic resection was not associated with survival advantages (median OS: 50 vs 45 months; 5-year OS: 38% vs 39%), a significant recurrence-free interval was seen.

There is no publication that reported on the survival impact of microscopy invasion into vascular or lymphatic structures. Besides the widely accepted residual classification (R0, R1 and R2) for microscopic invasion into the surgical field, we believe that this characteristic should be part of a standard histological review in order to further explore its utility as possible selection criteria for further intervention.

The negative long-term survival effect of postoperative hormonal treatment (idiopathic menopausal state) has never been presented or investigated given the historically documented marginal survival rate of these patients with conventional systemic treatment only. It is known that (early) menopausal state is related to an increased risk of a variety of diseases including cardiovascular disease and this might explain this finding \[[@CR40]\]. Given the rise in acceptance of hepatic resection for breast cancer liver metastases, more investigation in a larger cohort will shed more light into whether the benefit of hormonal therapy outweighs the risks in this subset of patients.

Among the patients that survived beyond 5 years we found a higher rate of recurrences but also a higher rate of repeat hepatectomy. This result confirms the importance of an aggressive approach through multiple hepatectomies when surgically possible. The potential benefit of repeat hepatectomy has been presented in a previous published work \[[@CR41]\].

It remains controversial to explore the idea of cure given the complexity of the disease and the notion that total eradication of disseminated cell is very unlikely. A cure model was used to compare the hazard rate of our highly selected group of patients to that of the general population. We found that 19 patients (14%) of the whole series had their chance of death reduced to that of the general population. This outcome has never been reported for breast cancer liver metastases patients treated by systemic treatment alone. This result further strengthens the indication for hepatic resection in patients with BCLM.

Our results might be based on our highly selected population but should not be dismissed as selection bias since these results are rarely achieved by conventional palliative therapy. Our study should serve as a guide to select women who might and might not benefit from an aggressive approach and stimulate future studies.

In conclusion, we believe that hepatectomy for BCLM should be considered in all patients when technically feasible and responding to systemic treatment. The current study shows that hepatectomy provides a chance of extreme long-term survival or even statistical cure in selected patients without increased morbidity. Something that was unthinkable within the current palliative approach to BCLM patients. Accurate selection of patients for hepatectomy remains crucial.
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